Cancer cell-autonomous cGAS-STING response confers drug resistance

Cell Chem Biol. 2023 Jun 15;30(6):591-605.e4. doi: 10.1016/j.chembiol.2023.05.005. Epub 2023 May 31.

Abstract

The cGAS-STING pathway has long been recognized as playing a crucial role in immune surveillance and tumor suppression. Here, we show that when the pathway is activated in a cancer-cell-autonomous response manner, it confers drug resistance. Targeted or conventional chemotherapy drugs promoted cytosolic DNA accumulation in cancer cells, activating the cGAS-STING pathway and downstream TBK1-IRF3/NF-κB signaling. This cancer cell-intrinsic response enabled the cells to counteract drug stress, allowing treatment resistance to be acquired and maintained. Blockade of stimulator of interferon genes (STING) signaling delayed and overcame resistance in models in vitro and in vivo. This finding uncovers an alternative face of cGAS-STING signaling other than the well-reported modulation of microenvironmental immune cells. It also implies a caution for the combination of STING agonist with targeted or conventional chemotherapy drug treatment, a strategy prevailing in current clinical trials.

Keywords: Cancer cell-autonomous; Drug resistance; STING; cGAS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • DNA / metabolism
  • Drug Resistance, Neoplasm*
  • Membrane Proteins* / metabolism
  • NF-kappa B / metabolism
  • Neoplasms* / drug therapy
  • Nucleotidyltransferases* / metabolism
  • Signal Transduction

Substances

  • DNA
  • NF-kappa B
  • Nucleotidyltransferases
  • cGAS protein, human
  • STING1 protein, human
  • Membrane Proteins